Sanofi has taken a small step towards potentially overturning a recent rejection by NICE for NHS use of Sarclisa as a ...

Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...

" I’m honored to join Innate Pharma at such a pivotal moment in its evolution,”said Jonathan Dickinson, Chief Executive Officer of Innate Pharma. “ We achieved notable regul ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

Sanofi SNY announced that the FDA has approved the label expansion for the use of its multiple myeloma (MM) drug, Sarclisa (isatuximab). With this nod, Sarclisa is now approved in combination with ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

Within the Sanofi antibody collaboration ... like bispecifics odronextamab (lymphoma) and linvoseltamab (multiple myeloma), which are both likely to reach the market in 2025, and a pipeline ...

Sanofi is deepening its commitment to targeted ... including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas. The scope of the research will also ...

Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

including rare cancers such as multiple myeloma, acute myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. Sanofi and Orano Med are members of the Paris ...